Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report) were down 0.7% during trading on Thursday . The stock traded as low as $14.53 and last traded at $14.88. Approximately 1,809,148 shares traded hands during mid-day trading, an increase of 435% from the average daily volume of 337,931 shares. The stock had previously closed at $14.99.
Silverback Therapeutics Stock Performance
The stock has a market cap of $536.54 million, a price-to-earnings ratio of -6.15 and a beta of 0.60. The stock's 50 day moving average is $12.22 and its two-hundred day moving average is $13.00.
About Silverback Therapeutics
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Further Reading
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
